To kick things off, we'll set the stage on what defines non-muscle invasive bladder cancer and how we triage patient ...

(Reuters) -Pfizer and Japanese firm Astellas' drug Padcev, combined with Merck's Keytruda, lowered the risk of tumor ...

Median disease-free survival (DFS) increased from 4.8 months with placebo to 9.9 months with adjuvant atezolizumab (Tecentriq ...

The BladderPath trial indicates that mpMRI can expedite MIBC treatment and improve bladder cancer-specific survival compared to traditional TURBT. The study showed a significant improvement in BCSS ...

Results presented by AstraZeneca from its phase 3 trial of Imfinzi in patients with high-risk, non-muscle invasive bladder ...

Bladder cancer is often overlooked, but a recent high-profile diagnosis is helping raise awareness. Football legend and Colorado head coach Deion Sanders recently revealed he had been diagnosed at age ...

This is the first meta-analysis comparing the overall survival of patients with limited-stage small cell bladder cancer who underwent radical surgery with platinum-based perioperative chemotherapy vs ...

Nearly 84,000 Americans will receive a bladder cancer diagnosis this year, yet most people remain unaware of the early warning signs that could save their lives. This silent disease often masquerades ...

Tecentriq reduced the risk of death by 41% and the risk of disease recurrence or death by 36% compared with placebo –– ...

Bladder cancer is one of the most common cancers worldwide. Men are around four times more likely to develop it than women, ...